TC BioPharm Limited Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Loss before tax

Loss before tax

12 Months Ended

Dec. 31, 2021

Loss before tax

5.	Loss before tax

Loss before tax is stated after charging the following:

Schedule of operating loss

		Year ended December 31,				Year ended December 31,				Year ended December,31
		2021				2020				2019
		£				£				£
Included in research and development costs:
Depreciation of property, plant and equipment			730,730				784,099				636,826
Amortization of intangible assets			63,451				51,889				52,847
Amortization of right of use assets			174,953				172,987				160,638

Included in administrative expenses:
(Gain)/loss on foreign exchange			(17,781	)			1,891				61,922
Depreciation of property, plant and equipment			34,301				42,651				32,253
Amortization of right of use assets			21,623				23,589				21,905